Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure

Cardiovascular Revascularization Medicine

Volumn 7, Issue 4, 2006, Pages 234-236

  Ajani, Andrew E ^a,b   Marwick, Thomas H ^c   Krum, Henry ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aldosterone antagonists; Heart failure; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM; SPIRONOLACTONE;

AGE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; IMPOTENCE; MENSTRUATION DISORDER; MORTALITY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK REDUCTION;

ALDOSTERONE ANTAGONISTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; SPIRONOLACTONE;

EID: 33845446376     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2006.07.002     Document Type: Article

References (11)

1. Steg P., Dabbous O., Feldman L., Cohen-Solal A., Aumont M., López-Sendón J., Budaj A., Goldberg R., Klein W., Anderson F., and for the Global Registry of Acute Coronary Events (GRACE) Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
2. Hasdai D., Topol E., Kilaru R., Battler A., Harrington R., Vahanian A., Ohman E., Granger C., Van de Werf F., Simoons M., O'connor C., and Holmes D. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 1 (2003) 73-79
3. Pitt B., Zannad F., Remme W., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
4. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
5. Pitt B., White H., Nicolau J., Martinez F., Gheorghiade M., Aschermann M., van Veldhuisen D., Zannad F., Krum H., Mukherjee R., Vincent J., and EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 3 (2005) 425-431
6. Borghi C., Bacchelli S., Esposti D., Bignamini A., Magnani B., and Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens 12 7 (1999) 665-672
7. Dargie H. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 9266 (2001) 1385-1390
8. Solomon S., Zelenkofske S., McMurray J., Finn P., Velazquez E., Ertl G., Harsanyi A., Rouleau J., Maggioni A., Kober L., White H., Van de Werf F., Pieper K., Califf R., Pfeffer M., and Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 25 (2005) 2581-2588
9. Cannon C., Weintraub W., Demopoulos L., et al., TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 25 (2001) 1879-1887
10. Wallentin L., Lagerqvist B., Husted S., Kontny F., Stahle E., and Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease. Lancet 356 9223 (2000) 9-16
11. Juurlink D., Mamdani M., Lee D., Kopp A., Austin P., Laupacis A., and Redelmeier D. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 6 (2004) 543-551